... data from its Phase II ACE‑Breast-03 study during a Spotlight Poster Presentation at the 2022 San Antonio Breast Cancer Symposium (SABCS).
News
- New data on breast cancer candidate sends Ambrx Biopharma skyward - The Pharma Letter
- MonarchE Update Benefit of Abemaciclib Increases Over Time - The ASCO Post
... the data at the 2022 San Antonio Breast Cancer Symposium (Abstract GS1-09). ... Eisai, AstraZeneca, Roche, Eli Lilly, and Puma Biotechnology.
- When loved ones become strangers | TPR - Texas Public Radio
Bioscience-Medicine RelationshipsTop Stories ... San Antonio soccer fans join the Men's World Cup's global audience. Stay Connected.
- Cemiplimab Plus REGN3767 and Chemo Shows Promise for HER2- Breast Cancer
... hormone receptor (HR)-positive, HER2-negative breast cancer, according to research presented at the San Antonio Breast Cancer Symposium 2022.
- Elacestrant vs Endocrine Monotherapy in Advanced Breast Cancer: Phase III EMERALD Trial
... colleagues at the 2022 San Antonio Breast Cancer Symposium (Abstract GS3-01). ... Gilead Sciences, Novartis, Pfizer, and Puma Biotechnology.